Valneva’s inactivated COVID-19 vaccine candidate shown to neutralize Omicron Variant
Preliminary laboratory studies demonstrate that three doses of Valneva’s inactivated COVID-19 vaccine candidate VLA2001 induced neutralization of the Omicron variant.... View Article
New member | PhosphoTech
PhosphoTech Laboratories is an international player specialising in the production of high added value marine ingredients. The company is based... View Article
New member | Stimul’in
The mission of Stimul’in is to enhance the daily life of people with neurocognitive troubles, their families and their health... View Article
InFlectis BioScience receives approval from the French regulatory authority to conduct a phase 2 clinical trial for IFB-088 (Icerguastat) for the treatment of Amyotrophic Lateral Sclerosis
InFlectis BioScience, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), receives approval from the... View Article
Valneva confirms clinical trial and regulatory submission timelines for its inactivated COVID-19 vaccine candidate VLA2001
Valneva, a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its... View Article
New member | Exportis
Exportis, based in Angers, is a marketing and sales services platform for startups and SMEs in the health sector, wishing... View Article
The PhagECOLI project undertaken by Pherecydes Pharma and the CEA receives a €2 million grant from Bpifrance
The project has won the “Emerging Infectious Diseases and New Radiological, Biological and Chemical Threats” Call for Expressions of Interest... View Article
Vincent Procaccio – Head of the Department of Genetics at Angers University Hospital, joins KetoM+
His remarkable professional skills and personality will be a great addition to our team and a critical asset for the... View Article
Pherecydes Pharma obtains ANSM approval for its PhagoDAIR program, the world’s first study in precision phage therapy
PhagoDAIR is a phase I/II clinical study with anti-Staphylococcus aureus phages in the treatment of osteoarticular infections of prostheses caused... View Article
Valneva announces positive lot-to-lot consistency trial results for its single-shot Chikungunya vaccine candidate
Valneva, a specialty vaccine company, announced positive topline results from the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine... View Article